Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials. The company is based in London, United Kingdom.